173 related articles for article (PubMed ID: 15881481)
1. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
4. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
6. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
Karnon J; Holmes MW; Williams R; Bakhai A; Brennan A
Int J Cardiol; 2010 Apr; 140(3):315-22. PubMed ID: 19106007
[TBL] [Abstract][Full Text] [Related]
7. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
Karnon J; Bakhai A; Brennan A; Pandor A; Flather M; Warren E; Gray D; Akehurst R
Int J Cardiol; 2006 May; 109(3):307-16. PubMed ID: 16026869
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
[TBL] [Abstract][Full Text] [Related]
10. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
[TBL] [Abstract][Full Text] [Related]
11. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
13. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
[TBL] [Abstract][Full Text] [Related]
14. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Haldemann R; Lüscher TF; Szucs TD
Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
[TBL] [Abstract][Full Text] [Related]
15. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Berger K; Hessel F; Kreuzer J; Smala A; Diener HC
Curr Med Res Opin; 2008 Jan; 24(1):267-74. PubMed ID: 18053318
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Schleinitz MD; Heidenreich PA
Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
